ARS Pharmaceuticals, Inc (SPRY)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $391.06M
Last updated: Nov 17, 2026 at 11:06 AM ET
ARS Pharmaceuticals, Inc (SPRY) Financials: Revenue, Profit and Cash Flow
ARS Pharmaceuticals reported revenue of $84.28M for the fiscal year ended Dec 31, 2025, down 5.5% from the year before. That year, net income was -$171.30M with a net margin of -203.3%, operating cash flow was -$170.87M and free cash flow was -$171.21M. The quarter ended Sep 30, 2026 had revenue of $37.71M and net income of -$35.59M.
Revenue and Margins
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $84.28M | -5.5% | 100.0% | -212.9% | -203.3% |
| Dec 2024 | $89.15M | +297063.3% | 98.9% | -3.5% | 9.0% |
| Dec 2023 | $30.00K | -97.7% | 100.0% | -225066.7% | -181216.7% |
| Dec 2022 | $1.32M | -76.1% | 100.0% | -2698.8% | -2635.4% |
| Dec 2021 | $5.51M | N/A | 100.0% | -353.3% | -367.7% |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | N/A | N/A | N/A | N/A | N/A |
| Dec 2018 | N/A | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $84.28M | $89.15M | $30.00K | $1.32M | $5.51M | $0 | N/A | N/A |
| Cost of revenue | $0 | $977.00K | $0 | $0 | $0 | $0 | $1.55M | $1.42M |
| Gross profit | $84.28M | $88.17M | $30.00K | $1.32M | $5.51M | $0 | -$1.55M | -$1.42M |
| Research and development | $13.18M | $19.58M | $20.27M | $18.38M | $20.27M | $24.58M | $21.50M | $14.80M |
| Operating income | -$179.45M | -$3.08M | -$67.52M | -$35.52M | -$19.45M | -$32.92M | -$24.07M | -$18.32M |
| Net income | -$171.30M | $8.00M | -$54.37M | -$34.68M | -$20.24M | -$32.95M | -$23.97M | -$17.58M |
| EBITDA | -$175.53M | $1.11M | -$61.14M | -$34.22M | N/A | -$32.25M | -$22.52M | -$16.90M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $37.71M | $33.66M | $22.68M | $28.09M | $32.50M | $15.72M | $7.97M | $86.58M | $2.07M | $500.00K | $0 | -$30.00K |
| Gross profit | $27.61M | $20.81M | $16.39M | $29.18M | $24.31M | $10.73M | $6.88M | $85.60M | $2.07M | $500.00K | $0 | -$3.40M |
| Operating income | -$34.17M | -$61.47M | -$60.15M | -$41.47M | -$53.19M | -$47.61M | -$37.18M | $47.20M | -$21.75M | -$15.34M | -$13.19M | -$10.23M |
| Net income | -$35.59M | -$62.34M | -$60.62M | -$41.32M | -$51.15M | -$44.88M | -$33.94M | $49.93M | -$19.13M | -$12.52M | -$10.29M | -$7.17M |
Balance Sheet
As of Dec 2025, total debt of $96.96M exceeded cash and equivalents by $55.65M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $327.65M | $351.15M | $233.19M | $281.44M | $61.45M | $394.80M | $15.65M | $27.55M |
| Current assets | $284.90M | $334.30M | $231.73M | $277.70M | $60.73M | $390.66M | $10.53M | $20.78M |
| Cash and equivalents | $41.32M | $50.82M | $70.97M | $210.52M | $60.06M | $386.57M | $9.98M | $20.16M |
| Total liabilities | $213.39M | $94.36M | $2.43M | $8.55M | $16.68M | $11.93M | $21.25M | $9.35M |
| Short-term debt | $588.00K | $42.00K | $0 | $230.00K | $3.48M | $844.00K | $12.30M | $3.53M |
| Long-term debt | $96.37M | $0 | N/A | N/A | $4.93M | $7.46M | N/A | N/A |
| Shareholder equity | $114.26M | $256.80M | $230.76M | $272.89M | -$31.27M | $382.88M | -$5.60M | $18.20M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $251.48M | $249.50M | $287.57M | $327.65M | $372.80M | $313.47M | $327.32M | $351.15M | $217.60M | $221.97M | $227.58M | $233.19M |
| Total liabilities | $263.44M | $236.98M | $226.26M | $213.39M | $225.15M | $121.15M | $98.34M | $94.36M | $16.62M | $6.72M | $3.71M | $2.43M |
| Cash and equivalents | $25.62M | $8.16M | $24.32M | $41.32M | $59.56M | $51.54M | $39.86M | $50.82M | $39.66M | $36.63M | $56.01M | $70.97M |
| Shareholder equity | -$11.96M | $12.51M | $61.31M | $114.26M | $147.66M | $192.32M | $228.97M | $256.80M | $200.98M | $215.24M | $223.87M | $230.76M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$170.87M | $13.55M | -$59.27M | -$40.08M | -$17.56M | -$31.20M | -$18.90M | -$16.88M |
| Capital expenditures | $339.00K | $563.00K | $175.00K | $199.00K | $55.00K | $917.00K | $96.00K | $449.00K |
| Free cash flow | -$171.21M | $12.98M | -$59.44M | -$40.28M | -$17.62M | -$32.11M | -$18.99M | -$17.32M |
| Investing cash flow | $56.77M | -$106.10M | -$87.18M | -$199.00K | -$55.00K | -$917.00K | -$96.00K | -$449.00K |
| Financing cash flow | $104.60M | $72.40M | $6.90M | $190.73M | $53.16M | $408.51M | $8.61M | $19.40M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$33.71M | -$60.93M | -$44.95M | -$43.48M | -$47.05M | -$39.59M | -$40.74M | $42.00M | -$14.47M | -$7.28M | -$6.71M | -$17.41M |
| Capital expenditures | N/A | N/A | $0 | $0 | $197.00K | $51.00K | $91.00K | $302.00K | $140.00K | $38.00K | $83.00K | $91.00K |
| Free cash flow | N/A | N/A | -$44.95M | -$43.48M | -$47.24M | -$39.64M | -$40.83M | $41.70M | -$14.61M | -$7.32M | -$6.79M | -$17.50M |
Frequently Asked Questions About SPRY
What is ARS Pharmaceuticals' annual revenue?
ARS Pharmaceuticals reported revenue of $84.28M for the fiscal year ended Dec 31, 2025.
How fast is ARS Pharmaceuticals' revenue growing?
Revenue was down 5.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 300.1%.
Is ARS Pharmaceuticals profitable?
No. ARS Pharmaceuticals reported net income of -$171.30M for the fiscal year ended Dec 31, 2025, with a net margin of -203.3%.
How much free cash flow does SPRY generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$170.87M minus capital expenditures of $339.00K produced free cash flow of -$171.21M.
How much debt does ARS Pharmaceuticals have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $96.37M, short-term debt of $588.00K and cash and equivalents of $41.32M.
SPRY pages: Overview, Earnings, Forecast, Financials, Competitors